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Abstract Glomerulonephritis is an important extrahepatic
manifestation of chronic hepatitis B virus (HBV) infection.
The uncommon occurrence, variability in renal histopatholo-
gy, and heterogeneity in clinical course present challenges in
clinical studies and have resulted in a relative paucity of data
and uncertainty with regard to the optimal management of
HBV-related glomerular diseases. The advent of nucleos(t)ide
analogue medications that effectively suppress HBV replica-
tion has markedly altered the clinical outcomes of kidney
transplant recipients with HBV infection, but the emergence
of drug resistance is an escalating problem. This article
reviews the recent knowledge of the pathogenesis and
treatment of HBV-related membranous nephropathy, and
discusses the management of hepatitis B in kidney transplant
recipients, which is continuously evolving.
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Introduction
The hepatitis B virus (HBV) has a complex relationship to
kidney diseases. Chronic HBV infection is an etiologic
factor in secondary glomerular diseases. From an opposite
perspective, the HBV carrier status has a critical impact on
the clinical management of kidney transplant recipients and
patients with renal diseases who are treated with immuno-
suppressive drugs.
HBV is not directly cytopathic to hepatocytes. The host
immune response, especially via virus-specific cytotoxic T
lymphocytes, is the basis for hepatocellular damage as well
as viral clearance. Neonatal exposure to HBV when the
immune system is immature results in minimal acute
hepatitis, but this is followed by chronic infection in 90%
of subjects, and contributes to the bulk of chronic HBV
carriers. After entering hepatocytes by endocytosis, the
partially double-stranded viral genomic DNA is transported
into the nucleus, where it is converted to covalently closed
circular DNA, which serves as a template for transcription
of viral mRNAs, which in turn are used for viral replication
through reverse transcription and the production of viral
DNA polymerase and other viral proteins. Intrahepatic
covalently closed circular DNA thus accounts for the
persistence of infection. About 350 million people world-
wide have chronic HBV infection. The importance of HBV
in clinical nephrology increases markedly in areas with
endemic infection such as South East Asia, where the
proportion of chronic HBV carriers can exceed 10% in the
general population. In this regard, data from a recent series
that included 390 patients with membranous nephropathy
showed that HBV was the underlying cause in 12% of
patients [1]. This article reviews the clinical and therapeutic
aspects of HBV-related glomerulonephritis focusing on
membranous nephropathy, kidney transplantation with
HBsAg-positive donors, and the evolving management of
hepatitis B in kidney transplant recipients.
HBV-related Glomerulonephritis
Extrahepatic manifestations of HBV infection can present
as glomerulonephritis, vasculitis, or reactive arthritis.
Glomerular disease is more common in children than
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adults, and in men than women [2]. The more common
renal histopathologies include membranous nephropathy
and membranoproliferative glomerulonephritis. An associ-
ation with IgA nephropathy has been reported, and recent
reports also suggest a possible link with focal segmental
glomerulosclerosis [3].
Pathogenic Mechanisms
Both viral and host factors are involved in pathogenesis. An
association with HLA genes has been reported, indicating
the impact of genetic predisposition [4]. The main
pathogenic mechanism in HBV-related glomerular diseases
is through the deposition of immune complexes in the
glomerulus. The immune complexes are comprised of viral
antigens and the antibodies that these antigens invoke from
the host. Whether these immune complexes are formed in
situ or are derived from circulating immune complexes
being trapped in the glomerulus remains controversial.
Various HBV antigens including hepatitis B surface antigen
(HBsAg), hepatitis B early antigen (HBeAg), and hepatitis
B core antigen (HBcAg) have been demonstrated in the
glomeruli of patients with HBV-related glomerulonephritis,
and the detection of covalently closed circular DNA in
renal tissue has also been reported [5]. Immune deposition
occurs predominantly in the subepithelial region but can
also involve the mesangial and occasionally subendothelial
areas, depending on the size of the antigens and immune
complexes. It has been speculated that the low molecular
weight of HBeAg (3×105 Da) might account for its ability
to traverse the glomerular basement membrane and thus the
formation of subepithelial immune deposits [6]. The
observed association between remission of proteinuria and
clearance of HBeAg also provides indirect evidence that the
antigen is involved in pathogenesis. The immune com-
plexes then activate complements and glomerular injury
occurs via the formation of membrane attack complex and
other downstream events such as the induction of proteases,
oxidation injury, and disruption of cytoskeleton [7, 8].
Investigations on renal gene expression profile with micro-
arrays, in transgenic mice that expressed HBsAg and
HBcAg in the cytoplasm of renal tubular epithelial cells
but without replication of the whole virus, have revealed
upregulation of complement and coagulation pathways and
acute phase response genes, and reduced circulating C3
levels [9].
It has been reported that the sera of patients with chronic
HBV infection could induce apoptosis in cultured HK-2
cells, a cell line for the study of human proximal renal
tubular epithelial cells, via up-regulation of Fas gene
expression [10]. Furthermore, the induction of apoptosis
correlated with the level of circulating HBV DNA, and
HBV carriers also showed a higher circulating level of
transforming growth factor-beta, a growth factor implicated
in the potentiation of apoptosis and renal fibrosis. These
preliminary data suggest the presence of serum factor(s) in
HBV carriers which could alter renal tubular cell function,
and should be confirmed using samples from patients with
documented nephritis and in podocytes.
HBV can be classified into eight major genotypes based
on genome sequence divergence. The impact of viral
genetics was recently investigated in a study that included
two pediatric and four adult Japanese patients, five of
whom had membranous nephropathy, and one with mem-
branoproliferative glomerulonephritis [11]. All the patients
were HBeAg-positive and had high circulating HBV DNA
levels. The investigators did not find any association
between nephropathy and mutations in the HBV genome.
However, the genotyping results were interesting. Previous
studies showed that genotype C was predominant among
local subjects with chronic hepatitis B, whereas genotype A
accounted for only 1.7% [12]. Yet complete viral genome
sequencing showed that among the patients with nephrop-
athy four had HBV genotype A1/A2, whereas two were
infected with genotype C2. A high prevalence of genotype
A in patients with HBV-related nephropathy had been
reported by other investigators [13, 14]. Whether HBV
genotype A may indeed be more likely to lead to renal
manifestations compared with other genotypes, and the
mechanisms accounting for such difference, require further
investigations.
Clinicopathologic Features of HBV-related Membranous
Nephropathy and Membranoproliferative
Glomerulonephritis
Patients with HBV-related membranous nephropathy typical-
ly present with proteinuria, which could be in the nephrotic
range, and microscopic hematuria. Impaired renal function is
more common in patients with membranoproliferative glo-
merulonephritis. The natural history of HBV-related membra-
nous nephropathy appears different between children and
adults. In contrast to pediatric subjects, in whom spontaneous
remission of proteinuria is common and the renal function is
often well preserved, adult patients are more likely to have
progressive disease and up to one third of patients might
eventually develop renal failure [13, 15, 16]. A temporal
relationship between increased hepatitic activity and deteri-
oration of proteinuria has been observed in some patients
[17], and could be associated with cryoglobulinemia.
HBV-related membranous nephropathy is characterized
by thickened capillary wall and glomerular basement
membrane on light microscopy. Although this feature could
be subtle in the early stage, the capillary wall can assume a
rigid appearance in advanced disease. Immunofluorescent
staining and electron microscopy demonstrate granular IgG,
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C3, and some IgM staining in the subepithelial region along
the glomerular basement membrane accompanied by exten-
sive effacement of the podocyte foot processes, and in some
cases viral particles in various locations within the glomer-
ulus. Mesangial abnormalities are more common in second-
ary membranous nephropathy compared with the idiopathic
form. Mesangial expansion and capillary wall thickening
resulting in a lobular appearance of the glomerular tuft
characterize the light microscopic findings in membrano-
proliferative glomerulonephritis. The capillary wall also
demonstrates a double-contour appearance and hypercellu-
larity with interpositioning of cells. The latter may include
infiltrating monocytes and neutrophils. Immune deposits
containing IgG, complement components, and IgM appear
granular on immunofluorescent staining, and are located in
the subendothelial, mesangial, and paramesangial areas. In
addition to these electron-dense deposits, which could also
be present in the subepithelial region, albeit in smaller
amounts, electron microscopy also shows subendothelial
expansion and the formation of new basement membrane
material, which accounts for the double-contour appearance
on light microscopy. The subendothelial and mesangial
immune deposits trigger complement activation and in-
creased local expression of inflammatory and chemotactic
mediators, leading to the infiltration of inflammatory cells.
Treatment of HBV-related Membranous Nephropathy
Much of the data on the treatment of HBV-related
glomerular diseases came from patients with membranous
nephropathy, the most common histologic presentation,
whereas the data on membranoproliferative glomerulone-
phritis or focal segmental glomerulosclerosis remain largely
anecdotal. Treatment with interferon [14, 18–25] or
lamivudine [17, 26–28] has been reported to lead to a
reduction of proteinuria in patients, mostly children, with
HBV-related membranous nephropathy.
Conventional and pegylated interferon-α possess both
immunoregulatory and antiviral effects [29]. Interferon-α
activates cellular pathways that lead to breakdown of viral
RNA and enhances cell-mediated immune response toward
hepatocytes infected with HBV. Interferon treatment given
for 4–12 months was associated with sustained remission of
proteinuria in 20% to 100% of patients, clearance of
HBeAg in 20% to 80%, and a drop-out rate of 10% to
15%. Resolution of proteinuria was often associated with
clearance of HBeAg and/or HBsAg, and usually occurred
within 6 months of seroconversion [13, 23, 24]. However,
most of the reported data were anecdotal reports or data
from small series. Bias from selective publication of
positive results remains possible. There is also a general
impression that the results in adults may be less favorable
compared with children.
Nucleos(t)ide analogues such as lamivudine, telbivu-
dine, adefovir, entecavir, or tenofovir suppress HBV
replication through their inhibitory effect on viral DNA
polymerase. Because the deposition of immune complexes
within the glomerulus is perceived to play a pivotal role in
the pathogenesis of HBV-related nephropathy, reducing the
quantity of viral antigens and thereby reducing immune
complex deposition in the kidneys should (in theory)
ameliorate kidney damage. Compared with interferon,
nucleos(t)ide analogues offer the advantages of convenient
administration and high tolerability, but often require long-
term administration and could result in the selection of
drug-resistant HBV strains. Adefovir should be used with
caution in patients with renal impairment in view of its
nephrotoxicity, which is mediated through inhibitioin of
mitochondrial DNA replication resulting in disruption of
normal mitochondrial respiratory function in proximal
renal tubular epithelial cells. There are also uncommon
reports of renal tubular toxicity with tenofovir [30]. Even
fewer data exist regarding nucleos(t)ide analogues than
interferon on HBV-related nephropathy. The factors predic-
tive of treatment efficacy and the selection criteria for
treatment also remain undefined. Data from a recent report
on 10 patients with HBV-related membranous nephropathy
showed that lamivudine treatment was associated with
complete resolution of proteinuria in six patients [28].
However, the concomitant use of angiotensin-converting
enzyme inhibitors, angiotensin II receptor blockers, and
antihypertensive medications precluded definitive conclu-
sions on the renal effect of antiviral treatment. Future
studies on the effect of antiviral therapy on proteinuria or
renal survival should thus include concurrent controls with
comparable exposure to these potential confounders.
The renal prognosis is distinctly different between pediatric
and adult patients, with the incidence of chronic kidney
disease reported as less than 3% in children and up to 30% in
adult patients [13, 15]. The overall data suggest that a
favorable renal response to antiviral treatment seems more
likely in pediatric patients than adults, and in patients when
renal manifestations are accompanied by increased viral
replication, a high HBV DNA level, and hepatitic flare.
HBV and Kidney Transplantation
The prevalence of HBsAg seropositivity in the general
population varies from less than 1% in nonendemic areas to
more than 10% in regions with endemic infection.
Similarly, the prevalence of HBV carriers among patients
on dialysis varies from about 1% in the United States to
more than 10% in some Asian countries [31, 32]. The use
of kidneys from HBsAg-positive donors demands caution
to avoid transmission of infection via the allograft. HBsAg-
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positive kidney transplant recipients are at risk of enhanced
viral replication and exacerbation of the liver disease
consequent to immunosuppression.
HBsAg-positive Kidney Donors
The use of kidneys from HBsAg-positive donors has been
a controversial issue. In regions with endemic HBV
infection, HBsAg-positive subjects account for a signifi-
cant donor pool. With the availability of effective antiviral
nucleos(t)ide analogues, little disagreement exists on
kidney transplantation from an HBsAg-positive donor to
an HBsAg-positive recipient. However, there has been
concern over the safety of transplanting from an HBsAg-
positive donor to a recipient who is anti–HBs-positive, for
fear that the preexisting immunity might not be adequate
to combat the virus load transferred with the transplanted
kidney in the face of heavy immunosuppression. Data
from relatively small series, from our unit and others,
suggested that it was safe to transplant kidneys from
HBsAg-positive donors to anti–HBs-positive recipients
[33]. A recent report examined the outcomes of 65 anti–
HBs-positive subjects who had received kidney transplants
from HBsAg-positive deceased donors, and compared them
with 308 anti–HBs-positive subjects who had received
kidney transplants from HBsAg-negative deceased donors,
with an average follow-up of more than 3 years [34•]. All
kidney transplant recipients were given 400 units of anti-
HBV immunoglobulin at the time of surgery, and those who
had received HBsAg-positive kidneys had a second dose
1 month later. When the donor was HBV DNA-positive by
quantitative polymerase chain reaction assay, the recipients
were given a prolonged course of anti-HBV immunoglob-
ulin at 400 units weekly for 3 months and lamivudine for
6 months. Seroconversion to HBsAg-positivity occurred in
two patients, one in the donor HBsAg-positive group (the
donor was HBV DNA-negative) at 3 months and the other
in the donor HBsAg-negative group (the donor was also
anti–HBc-negative) within the first month. Baseline anti-
HBs levels in the two kidney recipients were 63.6 IU/L and
4.6 IU/L, respectively. The second patient seroconverted
back to become HBsAg-negative and anti–HBs-positive at
6 months after transplantation. Different investigators have
reported occult HBV infection in patients on long-term
dialysis, which can occur even in the presence of anti-HBs
[35, 36]. In this study, potential kidney recipients were
apparently monitored serially for their HBV DNA status,
although the sensitivity of detection was not stated. The
absence of viral gene sequence data precluded definitive
conclusions on whether the HBsAg seroconversions were
caused by de novo HBV infection. Nevertheless, the data
reaffirm the overall safety of transplanting kidneys from
HBsAg-positive donors to anti–HBs-positive recipients,
irrespective of whether the immunity has resulted from
prior natural infection or vaccination. However, the role of
perioperative anti-HBV immunoglobulin and antiviral med-
ications remains unclear.
HBV Infection in Kidney Transplant Recipients
HBV-related liver complications can present as de novo
infection, acute flare in patients with chronic infection,
fibrosing cholestatic hepatitis, chronic hepatitis, cirrhosis,
or hepatocellular carcinoma. The adverse impact of HBV
infection on clinical outcomes has been reported by
different investigators [37–40]. Surveillance for hepatocel-
lular carcinoma with regular α-fetoprotein measurement
and liver ultrasonogram is essential in view of the much
improved prognosis conferred by the diagnosis of early
tumor compared with advanced disease. Prevention and
surveillance of liver complications in HBsAg-positive
kidney transplant recipients is a lifelong process that starts
before kidney transplantation (Table 1).
Data from patients with hepatitis C infection showed that
interferon treatment could lead to a high incidence of renal
allograft failure [41]. Thus, prior to the advent of nucleos(t)
ide analogues, the lack of effective and safe treatment had
added to the clinical challenge in the management of
hepatitis B in kidney transplant recipients. The incidence of
chronic liver disease in HBsAg-positive kidney transplant
recipients was up to 80%, and about 60% of the mortalities
were from liver complications [37–40]. Our own data
showed that in the prelamivudine era, HBsAg-positive
kidney transplant recipients had excessive early mortality
rates within the first 2 years after transplantation compared
with HBsAg-negative controls, and the deaths were from
severe hepatitic flares brought about by heavy immunosup-
pression [40]. Although 43% of the HBsAg-positive patients
were HBeAg-positive at the time of kidney transplantation,
HBeAg status by itself could not serve as a reliable predictor
of liver complications, and severe complications could also
occur in HBeAg-negative subjects.
Monitoring and Treatment
The management of HBsAg-positive kidney transplant
recipients entails monitoring for the early diagnosis of liver
complications, especially with regard to hepatitic flare and
hepatocellular carcinoma, and the prevention of cirrhosis.
Hepatitic flares are preceded by accelerated viral replication
and increasing circulating HBV DNA levels, and the risk of
flare varies according to the level of concurrent immuno-
suppression. Fibrosing cholestatic hepatitis, an uncommon
but serious complication occurring in heavily immunosup-
pressed patients, is characterized by relatively mild eleva-
tions in serum transaminase levels but markedly elevated
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HBV DNA levels and a rapid progression to liver failure if
untreated. Serial quantitation of HBV DNA titer is thus
important for the early diagnosis of impending serious
acute liver complications. It has been shown that, compared
with prophylactic or preemptive treatment, salvage treat-
ment given after the onset of hepatic dysfunction was
associated with inferior clinical outcomes [42].
We have reported that serial monitoring of circulating
HBV DNA levels combined with nucleos(t)ide analogue
treatment in patients who showed an increasing viral load
was highly efficacious in reducing liver complications and
markedly improved the survival of HBsAg-positive kidney
transplant recipients [40]. If frequent monitoring of HBV
DNA level is not available, it is also acceptable to start
treatment prophylactically at the time of kidney transplan-
tation in view of the frequent occurrence of hepatitic flare
within the first 2 years after kidney transplantation in
HBsAg-positive subjects. Our latest results show that
nucleos(t)ide analogue treatment is associated with im-
proved long-term patient survival in HBsAg-positive
kidney transplant recipients, from 40% to 70% at 20 years,
and that the patient survival rates are similar between
HBsAg-positive and HBsAg-negative subjects transplanted
in the present era of nucleos(t)ide analogue treatments up to
10 years after transplantation (unpublished data). The
beneficial effect of antiviral treatment on patient survival
was confirmed in a series of 27 Korean patients who had
been treated with lamivudine when their HBV DNA levels
increased after kidney transplantation [43]. The 10-year
patient survival rates increased from 50% in those without
treatment to 85% in lamivudine-treated subjects.
In our previous studies, we started nucleos(t)ide ana-
logue treatment when HBV DNA level was at or above 105
copies/mL irrespective of normal transaminase levels, or in
the range of 102–105 copies/mL when the transaminase
level was elevated. The HBV DNA threshold for treatment
in nonimmunosuppressed subjects is constantly evolving.
In patients presenting with severe hepatitic flare, treatment
is recommended as long as HBV DNA is detectable. By
contrast, the HBV DNA threshold for treatment has been
set at 2,000 IU/mL or about 104 copies/mL in subjects with
compensated cirrhosis and normal transaminase levels
[44•]. In patients with precirrhotic liver disease, correlations
have been observed between the level of HBV DNA and
the risk of cirrhosis, hepatocellular carcinoma, and liver-
related mortaliy, and the risk ratio starts to increase when
the HBV DNA level exceeds 104 copies/mL. Poor out-
comes are predicted by persistently high HBV DNA levels
and the persistence of HBeAg [45, 46]. Treatment decisions
are thus informed by transaminase levels, HBV DNA
levels, HBeAg status, and liver histology, with HBV
DNA levels of 104–105 copies/mL regarded by most as
the threshold.
Lamivudine Resistance
Prolonged treatment with nucleos(t)ide analogues can lead
to the selection of drug-resistant HBV variants. Avoidance
of this problem might be accomplished with discontinua-
tion of treatment after stabilization, but this is feasible in
not more than half of the patients [40, 47]. Most patients
thus require continued treatment for an indefinite duration.
Table 1 Preventive and surveillance measures against HBV related complications in kidney transplant recipients
Phase Preventive/surveillance measures
Before kidney
transplantation
1. Hepatitis B vaccination in HBsAg-negative anti-HBs-negative patients with chronic kidney disease
2. Monitor ductal and parenchymal enzymes and α-fetoprotein levels, and perform periodic liver imaging, in
HBsAg-positive patients
3. Assay HBeAg and anti-HBe status, and HBV DNA level, when there is evidence of hepatitis or when
considering treatment, and preferably immediately before kidney transplantation
4. Liver biopsy for assessment of cirrhosis or hepatitis to be considered judiciously in view of the increased risk
of bleeding
At the time of kidney
transplantation
1. Safe to transplant kidney from HBsAg-positive donor to anti-HBs-positive recipient; role of perioperative anti-
HBV immunoglobulin unclear
2. HBsAg-positive kidney transplant recipients should be prescribed nucleos(t)ide analogue treatment either
a) prophylactically starting at the time of kidney transplantation, or
b) preemptively when the level of HBV DNA increases, with or without abnormal transaminase levels; a
preemptive approach necessitates frequent monitoring of HBV DNA level
After kidney transplantation 1. Monitor ductal and parenchymal enzymes and α-fetoprotein levels, and perform periodic liver imaging, in
HBsAg-positive patients
2. Measure HBV DNA level with varying frequency according to the degree of immunosuppression
3. Measure HBV DNA level when there is evidence of hepatitis or when drug resistance is suspected
HBeAg hepatitis B early antigen, HBsAg hepatitis B surface antigen, HBV hepatitis B virus
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We observed a cumulative drug resistance rate of 48% in
kidney transplant recipients who had received lamivudine
treatment for an average duration of 69 months [48]. Drug
resistance could not be predicted by patient demographics,
baseline HBeAg status or HBeAg seroconversion, or HBV
genotype, but was associated with a high pretreatment HBV
DNA titer, similar to what had been observed in non-
immunosuppressed individuals. Following the emergence
of drug resistance, both the HBV DNA and the transam-
inase levels showed a biphasic longitudinal profile, so that
an initial increase was followed by spontaneous gradual
improvement, with peak transaminase levels appearing later
than those of HBV DNA. About 80% of patients developed
hepatitic flares. It is noteworthy that the peak transaminase
level after the emergence of lamivudine resistance was
more than twice the level at baseline, and some patients
might develop potentially fatal complications during flare.
Thus treatment with alternative medications are indicated.
Similar to our experience, Korean investigators have
reported a 53% cumulative resistance rate in kidney
transplant recipients after 5 years of lamivudine treatment,
and in this series two patients died from hepatitic flares
after the emergence of drug resistance [43].
We recently reported our preliminary experience in the
management of kidney transplant recipients who developed
lamivudine resistance [49]. The data showed that, whereas
alternative agents such as entecavir or adefovir were mostly
effective, the suppression of viral load was less rapid
compared with the rate of HBV DNA decline in treatment-
naïve subjects. We used adefovir only in patients with
serum creatinine below 150 umol/L, and their kidney
function remained stable during short-term follow-up.
Similar to kidney transplant recipients, HBsAg-positive
patients with other kidney diseases that require immuno-
suppressive treatment are exposed to the risk of viral
activation and hepatitic flare. We have adopted a similar
protocol of HBV DNA monitoring and preemptive treat-
ment in patients with severe lupus nephritis who require
combination treatment with high-dose corticosteroid and a
cytotoxic agent, and have shown that this can effectively
prevent or abort hepatitic flares [50].
Conclusions
Although the incidence of new infection is decreasing
with the increasing practice of hepatitis B vaccination,
HBV infection is still a profound global problem and an
important cause of secondary glomerular diseases. The
data suggest that patients presenting with proteinuria
accompanied by active viral replication, a high viral load,
and active hepatitis are more likely to show renal benefit
following antiviral treatment. More data from adults, and
on nucleos(t)ide analogues, are awaited. By contrast, data
are accumulating to confirm the efficacy of nucleos(t)ide
analogue treatment in improving the survival of HBsAg-
positive kidney transplant recipients, given either pre-
emptively when HBV DNA level is increasing or
prophylactically from the time of transplantation. Quan-
titation of circulating HBV DNA level facilitates the
early diagnosis of hepatitic flare and the emergence of
resistance. The management of drug resistance, and the
threshold HBV DNA level for treatment, continue to
evolve with increasing clinical experience.
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